Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The macro-economic outlook is looking increasingly grim, with inflation and interest rates on the up. We have a continuing bear market, slow M&A activity and a very uncertain geo-political climate, so where will the investment opportunities will come from? If it were easy, it wouldn't be so much fun (or indeed so potentially lucrative).
Evaluate's Paul Verdin and Cem Baydar sat down with guest speaker Özgür Tuncer, Investment Partner at Ascension Life Fund, to address the key challenges facing biopharma investors. If you would like to revisit the data and review some of the key themes discussed, please download our webinar slides and on-demand video using the link below.
• Where are the safe havens in uncertain times?
• Has the IPO window slammed shut?
• How much longer will venture funding remain the bright spot?
• How can the investment community effectively prioritise early stage investments?
Head of Services
Cem Baydar, Ph.D
Chief Consulting Officer
Ascension Life Fund